46 in-patients were randomly allocated to kelfiprim ( trimethoprim 250 mg + sulfalene ( sulfamethopyrazine ) 200 mg ) or to co-trimoxazole ( trimethoprim 320 mg + sulfamethoxazole 1600 mg ) and were treated for 1-2 weeks under double-blind conditions .
C0041044
co-trimoxazole
C0041041
trimethoprim